Compare ELUT & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELUT | INCR |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 47.4M |
| IPO Year | 2020 | 2021 |
| Metric | ELUT | INCR |
|---|---|---|
| Price | $0.84 | $1.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 53.3K | 16.7K |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,293,000.00 | N/A |
| Revenue This Year | N/A | $69.54 |
| Revenue Next Year | $10.83 | $41.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.68 |
| 52 Week High | $2.50 | $1.77 |
| Indicator | ELUT | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 35.80 | 55.18 |
| Support Level | $0.51 | $0.85 |
| Resistance Level | $1.00 | $1.15 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 15.79 | 100.00 |
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.